PCSK9 and atherosclerosis: The mainstays of ASCVD risk reduction are therapeutic lifestyle modifications and lipid-lowering medications, namely HMG-CoA reductase inhibitors (statins), cholesterol absorption inhibitors (ezetimibe), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (evolocumab, alirocumab), and icosapent ethyl.